At what pace is the budesonide market growing, and what is its estimated value?
The budesonide market size has grown strongly in recent years. It will grow from $9.72 billion in 2024 to $10.36 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to the rising prevalence of respiratory diseases, increased awareness about inhaled corticosteroids, the introduction of budesonide-based combination therapies, the expansion of healthcare access and infrastructures, and the adoption of budesonide for off-label use in inflammatory bowel diseases.
The budesonide market size is expected to see strong growth in the next few years. It will grow to $13.25 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growing demand for effective treatments, development of novel drug delivery systems, increasing use of budesonide, rising geriatric population prone to asthma, and expansion of generic budesonide products. Major trends in the forecast period include the adoption of biologics and biosimilars, advancements in drug delivery systems, regulatory approvals for new formulations, the development of novel drug delivery systems, and technological development.
Get Your Free Sample of The Global Budesonide Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp
What are the top drivers to the rising demand in the budesonide market?
The increase in the prevalence of respiratory diseases is expected to propel the growth of the budesonide market going forward. Respiratory diseases refer to medical diseases that affect the organs and tissues that regulate gas exchange in air-breathing animals. The increase in the prevalence of respiratory diseases is due to rising air pollution, particularly exposure to particulate matter and allergens, which has a major impact on the prevalence of asthma and chronic obstructive lung disease. Budesonide is used in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation, improve airflow, and prevent symptoms such as wheezing and shortness of breath. For instance, in May 2024, according to the National Center for Health Statistics (NCHS), a US-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, the increase in the prevalence of respiratory diseases will drive the growth of the budesonide market.
How is the budesonide market segmented?
The budesonide market covered in this report is segmented –
1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications
Subsegments:
1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)
2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers
3) By Injectable Suspension: Pre-filled Syringes, Vials
4) By Tablets And Capsules: Oral Tablets, Oral Capsules
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report
Who are the top competitors in the budesonide market?
Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.
What significant trends should we anticipate in the budesonide market over the forecast period?
Major companies operating in the budesonide market are focusing on advancements in respiratory treatment, such as oral therapy, enhancing patient convenience, improving treatment adherence, and expanding therapeutic options for managing asthma and other respiratory conditions. Oral therapy budesonide is a formulation of budesonide taken by mouth, primarily used to treat inflammatory conditions. For instance, in February 2024, Takeda Pharmaceuticals, a Japan-based pharmaceutical company, announced that the Food and Drug Administration (FDA), a US-based federal agency, has authorized EOHILIA, a budesonide oral suspension, as the first and only FDA-approved oral medication for patients aged 11 and above with eosinophilic esophagitis (EoE). Additionally, the FDA approved EOHILIA 2 mg twice daily based on effectiveness and safety data from two multicenter, randomized, double-blind, parallel-group, placebo-controlled 12-week investigations in individuals aged 11 to 56 with EoE.
Which regional trends are influencing the budesonide market, and which area dominates the industry?
North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Budesonide Market Report 2025 Offer?
The budesonide market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Budesonide is a corticosteroid medication used to reduce inflammation in conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases (Crohn’s disease, ulcerative colitis), and allergic rhinitis. It works by suppressing the immune response and decreasing inflammation in the airways or digestive tract.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21121
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
